839 related articles for article (PubMed ID: 15963007)
1. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
2. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.
Scheen AJ
Drug Saf; 2005 Jul; 28(7):601-631. PubMed ID: 27722966
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
7. Antihyperglycaemic agents. Drug interactions of clinical importance.
Scheen AJ; Lefèbvre PJ
Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
[TBL] [Abstract][Full Text] [Related]
8. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Landgraf R
Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
[TBL] [Abstract][Full Text] [Related]
9. Management of antidiabetic medications in overdose.
Spiller HA
Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
11. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced disorders of glucose metabolism. Mechanisms and management.
Chan JC; Cockram CS; Critchley JA
Drug Saf; 1996 Aug; 15(2):135-57. PubMed ID: 8884164
[TBL] [Abstract][Full Text] [Related]
14. [Clinically important effects of oral antidiabetic drug interactions].
Drzewoski J; Kopff B
Pol Merkur Lekarski; 2000 Sep; 9(51):605-7. PubMed ID: 11126985
[TBL] [Abstract][Full Text] [Related]
15. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
16. Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.
Prescrire Int; 2015 May; 24(160):130-5. PubMed ID: 26034806
[TBL] [Abstract][Full Text] [Related]
17. The role of sulphonylureas in the management of type 2 diabetes mellitus.
Rendell M
Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
[TBL] [Abstract][Full Text] [Related]
18. Recent developments and emerging therapies for type 2 diabetes mellitus.
Evans AJ; Krentz AJ
Drugs R D; 1999 Aug; 2(2):75-94. PubMed ID: 10820647
[TBL] [Abstract][Full Text] [Related]
19. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
Dunn CJ; Peters DH
Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
[TBL] [Abstract][Full Text] [Related]
20. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
Setter SM; Iltz JL; Thams J; Campbell RK
Clin Ther; 2003 Dec; 25(12):2991-3026. PubMed ID: 14749143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
